Navigation Links
MacuLogix Raises $3.6 Million in Series A Round
Date:3/11/2013

HUMMELSTOWN, Pa., March 11, 2013 /PRNewswire/ -- MacuLogix, Inc., a pioneer in the early detection and tracking of age-related macular degeneration (AMD), today announced it has raised $3.6 million in Series A funding. Investors include Berwind Private Equity, Roche Venture Fund, Life Sciences Greenhouse of Central Pennsylvania, and Ben Franklin Technology Partners of Central and Northern Pennsylvania.

The funds will be used to accelerate manufacturing and commercial sales of the MacuLogix' AdaptDx™. The AdaptDx™ is being developed to be the first practical diagnostic for early detection and tracking of AMD. Based on significant advances in the measurement of dark adaptation, the AdaptDx™ will provide doctors with an easy-to-use, functional diagnostic similar to routine perimetry testing for glaucoma. With this important new tool, doctors will be able to intervene at the earliest possible time to prevent vision loss and improve quality of life.

"MacuLogix represents a favorable investment opportunity as it addresses a large and growing market for AMD which is the leading cause of adult vision loss and blindness in developed countries," said A. Laurence Norton , Managing Director of Berwind Private Equity. "We understand the AdaptDx™ has the potential to fundamentally transform the way eye doctors detect and manage AMD for millions of people worldwide."

"Closing our Series A round is a very significant achievement for the company," said John G. Edwards , CEO of MacuLogix. "We have completed numerous clinical studies involving more than 1,000 patients with additional studies ongoing, all at major research centers such as Harvard University, the National Eye Institute and University of Alabama at Birmingham. This financing allows us to take the next step."

About MacuLogix
MacuLogix is a pioneer in the early detection and tracking of age-related macular degeneration (AMD). MacuLogix' AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. However, the AdaptDx™ is not currently cleared for sale as a diagnostic. In addition, the AdaptDx™ is being used by a number of pharmaceutical companies in the development of drugs for early AMD. 

For more information, visit www.maculogix.com


'/>"/>
SOURCE MacuLogix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
2. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
3. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
4. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
5. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
6. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
7. Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
8. AssureRx Health Raises $12.5 Million Series C Financing
9. InnoPharma Inc. Raises $8 Million in Venture Debt
10. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
11. Retia Medical Raises $7 Million to Develop Accurate, Less-Invasive Cardiovascular Monitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):